Welcome to our dedicated page for Alpha Teknova news (Ticker: TKNO), a resource for investors and traders seeking the latest updates and insights on Alpha Teknova stock.
Alpha Teknova, Inc. reports recurring financial and operating updates as a life-sciences reagent manufacturer serving therapy, vaccine and molecular-diagnostics workflows. The company organizes revenue around Lab Essentials and Clinical Solutions, with products that include agar plates, microbial culture and cryopreservation media, buffers, molecular biology reagents and water used across research-use and GMP production settings.
Company news commonly covers quarterly and annual results, revenue guidance, segment performance, Clinical Solutions customer activity, cash use, borrowings and free cash flow. Updates also describe Teknova’s modular manufacturing platform and its role in supplying foundational reagents for genomics, synthetic biology, molecular diagnostics and emerging therapeutic modalities.
Teknova (Nasdaq: TKNO) reported Q1 2026 revenue of $11.1 million, up 13% year-over-year, driven by Clinical Solutions growth. Gross profit was $3.8 million and gross margin rose to 34.2%. Net loss was $4.6 million (negative $0.08 per diluted share). Adjusted EBITDA improved to negative $2.0 million. Cash and short-term investments were $17.8 million with total borrowings of $13.2 million. The company reaffirmed 2026 revenue guidance of $42–44 million and expects full-year Free Cash Outflow of less than $10 million.
Teknova (Nasdaq: TKNO) will report first quarter 2026 financial results on Wednesday, May 6, 2026, after market close. The company will host a webcast and conference call the same day beginning at 6:00 p.m. Eastern Time.
Live access and registration details are available via the Investor Relations section of Teknova's website; a replay will be posted about two hours after the event.
Teknova (Nasdaq: TKNO) reported full year 2025 revenue of $40.5M, up 7% year-over-year, and Q4 2025 revenue of $10.0M, up 8% year-over-year. The company provided 2026 revenue guidance of $42–44M and expects Free Cash Outflow of less than $10M for 2026.
Gross margin improved to 33.2% for 2025; Adjusted EBITDA loss narrowed to -$6.7M. Cash and short-term investments were $21.3M with gross debt of $13.2M at year-end.
Teknova (Nasdaq: TKNO) will report fourth-quarter and full-year 2025 financial results on February 26, 2026 after market close.
The company will host a live webcast and conference call on February 26, 2026 at 5:30 p.m. Eastern Time, with a replay available on the investor website about two hours after the event.
Teknova (Nasdaq: TKNO) reported Q3 2025 revenue of $10.5M, a 9% increase versus Q3 2024, marking five consecutive quarters of year‑over‑year revenue growth. Lab Essentials sales rose 16% to $8.3M while Clinical Solutions fell 13% to $1.7M. Gross profit was $3.2M and gross margin improved to 30.7% (versus 0.9% in Q3 2024, adjusted 29.8%). Net loss narrowed to $4.3M (‑$0.08/share). Adjusted EBITDA improved to ‑$1.6M and Free Cash Outflow was $2.4M for the quarter. Cash and short‑term investments were $22.1M with borrowings of $13.2M. The company reaffirmed 2025 revenue guidance of $39–42M and Free Cash Outflow $12M.
Teknova (Nasdaq: TKNO) will report third quarter 2025 financial results for the quarter ended September 30, 2025, on Thursday, November 6, 2025 after market close.
The company will host a webcast and conference call on November 6, 2025, beginning at 5:00 p.m. Eastern Time. Investors can access the live webcast from the Investor Relations section of Teknova's website or by using the provided link, and participants can register to receive a unique PIN and dial-in information. A replay of the webcast will be available on the company website about two hours after the event.
Teknova (Nasdaq: TKNO) reported strong Q2 2025 financial results with total revenue of $10.3 million, marking a 7% increase from Q2 2024. The company achieved four consecutive quarters of year-over-year growth and reaffirmed its 2025 revenue guidance of $39-42 million.
Key financial metrics include: Lab Essentials revenue of $7.8 million (up 2%), Clinical Solutions revenue of $2.1 million (up 32%), and improved gross margin of 38.7% compared to 29.2% in Q2 2024. The company reported a net loss of $3.6 million ($0.07 per share), showing improvement from the $5.4 million loss in Q2 2024. Cash position stands at $24.0 million with total borrowings of $13.2 million.
Teknova (Nasdaq: TKNO), a producer of critical reagents for therapies, vaccines, and molecular diagnostics, has scheduled its Q2 2025 financial results announcement for August 7, 2025, after market close.
The company will host a conference call and webcast at 5 p.m. Eastern Time on the same day. Investors can access the webcast through Teknova's Investor Relations website, and participants wanting to join the call need to register to receive dial-in information. A replay will be available approximately two hours after the event.
Teknova (Nasdaq: TKNO), a leading producer of critical reagents for therapy, vaccine, and molecular diagnostics development, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close. The company will host a webcast and conference call at 5 p.m. Eastern Time on the same day. Interested participants can access the webcast through Teknova's Investor Relations section and must register to receive a unique PIN for dial-in access. A replay will be available on the company's website approximately two hours after the event.